company background image
ACAD

ACADIA Pharmaceuticals NasdaqGS:ACAD Stock Report

Last Price

US$23.29

Market Cap

US$3.8b

7D

-4.6%

1Y

43.1%

Updated

25 Sep, 2023

Data

Company Financials +

ACADIA Pharmaceuticals Inc.

NasdaqGS:ACAD Stock Report

Mkt Cap: US$3.8b

ACAD Stock Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.

ACAD fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ACADIA Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ACADIA Pharmaceuticals
Historical stock prices
Current Share PriceUS$23.29
52 Week HighUS$33.99
52 Week LowUS$13.73
Beta0.57
1 Month Change-18.57%
3 Month Change-3.84%
1 Year Change43.06%
3 Year Change-42.11%
5 Year Change12.03%
Change since IPO247.61%

Recent News & Updates

Recent updates

Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

May 22
Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah

Oct 19

FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide

Sep 12

Acadia: Powerful Unfolding Catalysts

Aug 03

Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome

Jul 18

FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet

Jun 29

Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth

May 07
Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth

Acadia: Catalysts Stacking

Apr 28

Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right

Feb 22

Acadia: Big News On The Near Horizon

Dec 08

Acadia Pharmaceuticals: Refunding A Former Champion

Sep 29

Acadia's Essential Questions Heading Into Q2 2021 Earnings

Jul 30

Here's Why We Think ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation Looks Fair for the time being

Jun 16
Here's Why We Think ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation Looks Fair for the time being

Acadia's Big Reveal

May 10

Acadia maintains 2021 sales guidance as Q1 net sales rise 18%

May 05

Shareholder Returns

ACADUS BiotechsUS Market
7D-4.6%-1.5%-2.7%
1Y43.1%11.8%16.8%

Return vs Industry: ACAD exceeded the US Biotechs industry which returned 11.8% over the past year.

Return vs Market: ACAD exceeded the US Market which returned 16.8% over the past year.

Price Volatility

Is ACAD's price volatile compared to industry and market?
ACAD volatility
ACAD Average Weekly Movement8.4%
Biotechs Industry Average Movement9.1%
Market Average Movement5.5%
10% most volatile stocks in US Market14.2%
10% least volatile stocks in US Market2.5%

Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ACAD's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993540Steve Davishttps://acadia.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.

ACADIA Pharmaceuticals Inc. Fundamentals Summary

How do ACADIA Pharmaceuticals's earnings and revenue compare to its market cap?
ACAD fundamental statistics
Market CapUS$3.81b
Earnings (TTM)-US$110.81m
Revenue (TTM)US$550.90m

6.9x

P/S Ratio

-34.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACAD income statement (TTM)
RevenueUS$550.90m
Cost of RevenueUS$298.66m
Gross ProfitUS$252.24m
Other ExpensesUS$363.05m
Earnings-US$110.81m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.68
Gross Margin45.79%
Net Profit Margin-20.12%
Debt/Equity Ratio0%

How did ACAD perform over the long term?

See historical performance and comparison